Prism Medico & Pharmacy Ltd (512217)
🎯 Key Takeaways
- Prism Medico & Pharmacy Ltd appears to be in a nascent or developmental phase, with no consistent revenue or profitability trend and negative ROE and ROCE, suggesting it is either in early-stage operations or undergoing restructuring. The company has minimal assets and no debt burden, but financial performance remains highly volatile and unprofitable.
- Revenue grew 47.3% QoQ to ₹10 in Q3FY20.
- ⚠️ 1) Persistent unprofitability with negative ROE and ROCE raises concerns about capital efficiency. 2) Revenue volatility and lack of growth trend sugg
- Market Cap
- ₹39
- P/B Ratio
- 3.05
- ROE
- -5.0%
- ROCE
- -2.8%
- Debt/Equity
- 0.18
- Promoter
- 30.0%
📖 The Story
Prism Medico & Pharmacy Ltd appears to be in a nascent or developmental phase, with no consistent revenue or profitability trend and negative ROE and ROCE, suggesting it is either in early-stage operations or undergoing restructuring. The company has minimal assets and no debt burden, but financial performance remains highly volatile and unprofitable.
📰 What's Happening
Management has not disclosed any new strategic initiatives or operational expansions in recent filings. The company continues to operate with negligible revenue and margins, with no indication of scaling or diversification. Shareholding remains stable, with promoter holding declining slightly but no significant institutional interest observed.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 |
|---|---|---|---|---|
| Revenue | 17 | 9 | 7 | 10 |
| Operating Profit | -1 | 0 | 0 | 0 |
| OPM % | -4.4% | 0.9% | 2.3% | 0.0% |
| Net Profit | -1 | 0 | 0 | -0 |
| EPS | ₹-1.21 | ₹0.21 | ₹0.15 | ₹-0.07 |
Revenue has shown no sustainable growth, peaking at ₹17 crore in March 2019 before declining to ₹7-10 crore levels, with persistent operating losses and negative margins. Profitability remains nonexistent, and EPS has fluctuated without improvement, indicating operational instability without clear signs of recovery or scale.
🔮 Management Outlook & What's Next
There is no available forward guidance or explicit outlook from management in the provided filing content. No commentary on future revenue targets, profitability, or strategic direction has been disclosed in the latest filings.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2019 | Mar 2019 | Mar 2020 | Mar 2020 |
|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 |
| Reserves | 7 | 7 | 7 | 7 |
| Borrowings | 2 | 2 | 0 | 1 |
| Total Liabilities | 21 | 20 | 25 | 24 |
| Fixed Assets | 9 | 9 | 9 | 9 |
| Investments | 1 | 3 | 1 | 1 |
| Total Assets | 21 | 20 | 25 | 24 |
The balance sheet shows a very light capital structure with negligible borrowings and minimal equity and reserves, suggesting limited reinvestment or operational scale. Total assets have remained flat around ₹21–25 crore, reflecting a stagnant asset base with no visible expansion or capital expenditure activity.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2019 |
|---|---|
| Operating | -0 |
| Investing | 0 |
| Financing | -1 |
| Net Cash Flow | -1 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 25.0% | 25.5% | 30.0% |
| FII | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% |
| Public | 65.6% | 66.0% | 65.9% |
| # Shareholders | 4,306 | 4,295 | 4,177 |
Promoter holding has declined slightly from 29.98% to 25.49% over recent quarters, but remains concentrated. FII and DII holdings are consistently zero, indicating no institutional interest. The growing number of public shareholders suggests retail participation but no major investor accumulation.
⚖️ Peer Comparison — Trading
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent unprofitability with negative ROE and ROCE raises concerns about capital efficiency. 2) Revenue volatility and lack of growth trend suggest operational instability. 3) Absence of institutional interest may limit liquidity and confidence. 4) No disclosed growth strategy or management vision increases uncertainty about long-term viability.
📋 Recent Filings
- Announcement2026-09-30Prism Medico & Pharmacy Ltd announced that its insider trading window will close on October 1, 2026, and remain shut for 48 hours after the quarter an…
- 🔴 Corporate Action2026-09-30Prism Medico & Pharmacy Limited informed BSE and MSED that it will not issue any non-convertible securities with interest, dividend, or principal paya…
- 🟡 voting results2026-09-22At the 24th AGM held on 19 September 2026 via video conferencing, shareholders approved all 8 resolutions with near-unanimous support, including adopt…
- 🟡 Board Meeting2026-09-19The 24th Annual General Meeting of Prism Medico & Pharmacy Ltd was held on 19 September 2026 via video conference, where shareholders approved the aud…
- 🟡 Board Meeting2026-09-19Prism Medico & Pharmacy held its 24th Annual General Meeting on 19 September 2026 via video conference, where shareholders approved all resolutions in…
🧠 Analyst's Read
The company lacks a clear operational or financial trajectory, with no signs of scaling or path to profitability. Investors should monitor for any shift in strategy, revenue stabilization, or institutional interest, but current metrics offer limited visibility into future performance.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day